Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RPTX 
Repare Therapeutics Inc (RPTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/22/2025: RPTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.92% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 80.76M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 4 | Beta 1.07 | 52 Weeks Range 0.89 - 4.07 | Updated Date 10/22/2025 |
52 Weeks Range 0.89 - 4.07 | Updated Date 10/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8024.8% |
Management Effectiveness
Return on Assets (TTM) -38.82% | Return on Equity (TTM) -69.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -29778124 | Price to Sales(TTM) 323.05 |
Enterprise Value -29778124 | Price to Sales(TTM) 323.05 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 0.58 | Shares Outstanding 42959172 | Shares Floating 22715092 |
Shares Outstanding 42959172 | Shares Floating 22715092 | ||
Percent Insiders 1.25 | Percent Institutions 64.93 |
Upturn AI SWOT
Repare Therapeutics Inc
Company Overview
History and Background
Repare Therapeutics Inc. is a precision oncology company founded in 2015. It focuses on discovering, developing, and commercializing novel therapeutics targeting specific vulnerabilities of tumors in genetically defined patient populations. The company went public in June 2020.
Core Business Areas
- Oncology Drug Development: Discovery, development, and commercialization of precision oncology therapeutics. Focus on targeting specific DNA damage repair (DDR) pathways.
- SNIPRxu00ae platform: A proprietary, genome-wide CRISPR-enabled platform used to systematically discover and develop novel targeted therapies. The platform identifies novel synthetic lethal interactions.
Leadership and Structure
Repare Therapeutics Inc. is led by President and CEO Lloyd Segal. The organizational structure includes research, development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Camonsertib: A novel, oral ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) inhibitor currently in clinical trials for solid tumors with ATR inhibitor-sensitive mutations. Phase 1 and 2 trials are ongoing to evaluate its efficacy across different cancer types. Competitors include other pharmaceutical companies developing ATR inhibitors, such as Vertex Pharmaceuticals and Merck KGaA.
- RP-3470: A PKMYT1 inhibitor targeting tumors with CCNE1 amplification or FBXW7 loss. It's in Phase 1 clinical trials. Competitors include companies developing similar inhibitors, although RP-3470 potentially has differentiated qualities.
Market Dynamics
Industry Overview
The oncology market is experiencing significant growth driven by advancements in personalized medicine and targeted therapies. The demand for drugs targeting specific genetic mutations in tumors is increasing.
Positioning
Repare Therapeutics Inc. is positioned as a precision oncology company leveraging its SNIPRxu00ae platform to identify and develop novel targeted therapies. Its competitive advantage lies in its platform and pipeline focused on DDR pathways.
Total Addressable Market (TAM)
The total addressable market for precision oncology is estimated to be billions of dollars annually, growing as more specific genetic targets are identified and validated. Repare Therapeutics Inc. is positioning itself to capture a significant share of this market by focusing on novel targets and developing differentiated therapies.
Upturn SWOT Analysis
Strengths
- Proprietary SNIPRxu00ae platform
- Strong focus on DNA damage repair (DDR) targets
- Experienced management team
- Pipeline of novel targeted therapies
Weaknesses
- Limited number of products on the market
- Reliance on clinical trial success
- Cash burn associated with R&D expenses
- Competition from larger pharmaceutical companies
Opportunities
- Expansion of SNIPRxu00ae platform to discover new targets
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approvals
- Expansion into new geographic markets
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing similar therapies
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- MRK
- VRTX
- AZN
Competitive Landscape
Repare Therapeutics Inc. competes with both large pharmaceutical companies and other biotechnology companies in the precision oncology space. Its SNIPRxu00ae platform and focus on DDR targets provide a competitive advantage, but it faces challenges in securing funding and navigating regulatory hurdles.
Growth Trajectory and Initiatives
Historical Growth: Repare Therapeutics Inc.'s growth has been driven by its research and development activities, clinical trial progress, and partnerships. It is still a relatively young company and heavily reliant on success with their ongoing drug development.
Future Projections: Future growth projections depend on the success of its clinical trials and regulatory approvals of its product candidates. Analyst estimates vary and should be consulted for detailed forecasts.
Recent Initiatives: Recent strategic initiatives include advancing its clinical programs for camonsertib and RP-3470, expanding the SNIPRxu00ae platform, and seeking partnerships with other pharmaceutical companies.
Summary
Repare Therapeutics Inc. is a precision oncology company with a promising drug discovery platform and pipeline. Clinical trial outcomes are critical for future success, and they need to manage their cash burn. Competition from larger pharmaceutical companies poses a risk, but the potential for partnerships and expansion into new markets presents opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Repare Therapeutics Inc. website
- SEC Filings
- Financial News Sources
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market conditions and company performance are subject to change. The market share data is an estimation and may not be exact.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repare Therapeutics Inc
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2020-06-19 | President, CFO, CEO & Director Mr. Steve Forte CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 129 | Website https://www.reparerx.com |
Full time employees 129 | Website https://www.reparerx.com | ||
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.